Patents by Inventor Takayuki Miyano
Takayuki Miyano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11969662Abstract: There is provided a robot device including: a head portion coupled to a trunk; four leg portions on a front left, a front right, a rear left, and a rear right coupled to the trunk; a first indirect portion that tilts the head portion left and right; and a second joint portion that rotates, with respect to the trunk, one of the leg portions on the rear left and the rear right to a front side, and the other to a rear side. It is possible to faithfully reproduce the movement of the four-legged animal by providing the first joint portion and the second joint portion.Type: GrantFiled: September 6, 2018Date of Patent: April 30, 2024Assignee: SONY CORPORATIONInventors: Hidenori Ishibashi, Tomoo Mizukami, Takuma Araki, Masato Muraki, Tomoyuki Arai, Goushi Koike, Takayuki Ito, Kouta Katsumura, Yohei Watanabe, Muneyuki Horiguchi, Takashi Maeda, Satoshi Muto, Hideo Miyano
-
Patent number: 9724312Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.Type: GrantFiled: January 14, 2014Date of Patent: August 8, 2017Assignee: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Takahiro Kurose, Takayuki Miyano, Mariyo Kato, Yoshihiro Takai
-
Publication number: 20160136275Abstract: An ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent has an advantage that the loss of the geranylgeranylacetone content during long-term storage is very little. This is because of reduced adsorption of geranylgeranylacetone to a wall of an ophthalmic container. The ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent also has an advantage that adsorption of geranylgeranylacetone to a contact lens is little. Further, the ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent hardly becomes white turbid even when stored at low temperature.Type: ApplicationFiled: January 27, 2016Publication date: May 19, 2016Inventors: Takayuki MIYANO, Takahiro KUROSE
-
Patent number: 9320802Abstract: This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil in which the average number of moles of added ethylene oxide is 2 to 12 and (B) terpenoid. According to the present invention, an aqueous ophthalmic composition having an improved foam disappearance speed can be obtained.Type: GrantFiled: April 10, 2015Date of Patent: April 26, 2016Assignee: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Chinatsu Furumiya, Takayuki Miyano, Atsuko Nakata, Eri Matsumoto
-
Publication number: 20160089345Abstract: An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, the ophthalmic composition kit having an advantage that the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the ophthalmic composition is very little.Type: ApplicationFiled: December 9, 2015Publication date: March 31, 2016Inventors: Takayuki MIYANO, Takahiro KUROSE
-
Patent number: 9278062Abstract: An eye drop composition comprising a carboxyvinyl polymer and a monoterpene, and having a viscosity from 200 to 100,000 mPa·s. The monoterpene may be at least one selected from the group consisting of menthol, camphor and borneol. The carboxyvinyl polymer content may be from 0.001 to 10 w/v % with respect to the total volume of the eye drop composition, and the monoterpene content may be from 0.0001 to 1 w/v % with respect to the total volume of the eye drop composition.Type: GrantFiled: September 29, 2010Date of Patent: March 8, 2016Assignee: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Teiko Akagi, Takayuki Miyano, Motoyoshi Inooka
-
Publication number: 20150209437Abstract: This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil in which the average number of moles of added ethylene oxide is 2 to 12 and (B) terpenoid. According to the present invention, an aqueous ophthalmic composition having an improved foam disappearance speed can be obtained.Type: ApplicationFiled: April 10, 2015Publication date: July 30, 2015Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Chinatsu FURUMIYA, Takayuki MIYANO, Atsuko NAKATA, Eri MATSUMOTO
-
Patent number: 9034931Abstract: This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil in which the average number of moles of added ethylene oxide is 2 to 12 and (B) terpenoid. According to the present invention, an aqueous ophthalmic composition having an improved foam disappearance speed can be obtained.Type: GrantFiled: December 27, 2011Date of Patent: May 19, 2015Assignee: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Chinatsu Furumiya, Takayuki Miyano, Atsuko Nakata, Eri Matsumoto
-
Publication number: 20150025154Abstract: An ophthalmic composition comprising geranylgeranylacetone and a fat-soluble antioxidant has an advantage that adsorption of geranylgeranylacetone to a wall of a container is remarkably reduced and thereby the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the composition is remarkably reduced. Adsorption of the fat-soluble antioxidant to a wall of a container is also reduced due to combination with geranylgeranylacetone.Type: ApplicationFiled: October 6, 2014Publication date: January 22, 2015Inventors: Takayuki MIYANO, Takahiro KUROSE
-
Publication number: 20140350119Abstract: An ophthalmic composition comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone protects various types of retinal cells from degeneration, impairment or destruction, thereby remarkably promoting the survival. Consequently, the composition exhibits a remarkable effect of preventing, ameliorating or treating various retinal diseases. In addition, the composition hardly becomes white turbid during storage.Type: ApplicationFiled: August 15, 2014Publication date: November 27, 2014Inventors: Takayuki MIYANO, Takahiro KUROSE, Mariyo KATO, Yoshihiro TAKAI
-
Publication number: 20140302146Abstract: The present invention provides an ophthalmic aqueous composition having an oil-in-water emulsion including a vegetable oil, a non-ionic surfactant, and a terpenoid, wherein an average particle diameter of emulsion particles is within the range of 30 nm to 300 nm.Type: ApplicationFiled: July 5, 2012Publication date: October 9, 2014Applicant: ROHTO PHARMACEUTICAL CO.,LTD.Inventors: Takahiro Kurose, Takayuki Miyano, Toru Okubo, Mariyo Kato
-
Publication number: 20140243419Abstract: Application of a pharmaceutical preparation comprising geranylgeranylacetone to the mucosa of, for example, the eye, nose, oral cavity or pharynx can efficiently prevent, ameliorate or treat retinal diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration, and diabetic retinopathy.Type: ApplicationFiled: May 1, 2014Publication date: August 28, 2014Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Takahiro KUROSE, Yoshihiro TAKAI, Takayuki MIYANO, Yusuke TAKEUCHI
-
Publication number: 20140128475Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Takahiro KUROSE, Takayuki MIYANO, Mariyo KATO, Yoshihiro TAKAI
-
Publication number: 20140045948Abstract: An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, the ophthalmic composition kit having an advantage that the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the ophthalmic composition is very little.Type: ApplicationFiled: October 17, 2013Publication date: February 13, 2014Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Takayuki MIYANO, Takahiro KUROSE
-
Publication number: 20130303624Abstract: An ophthalmic composition comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone protects various types of retinal cells from degeneration, impairment or destruction, thereby remarkably promoting the survival. Consequently, the composition exhibits a remarkable effect of preventing, ameliorating or treating various retinal diseases. In addition, the composition hardly becomes white turbid during storage.Type: ApplicationFiled: February 25, 2013Publication date: November 14, 2013Inventors: Takayuki MIYANO, Takahiro KUROSE, Mariyo KATO, Yoshihiro TAKAI
-
Publication number: 20130296446Abstract: This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil in which the average number of moles of added ethylene oxide is 2 to 12 and (B) terpenoid. According to the present invention, an aqueous ophthalmic composition having an improved foam disappearance speed can be obtained.Type: ApplicationFiled: December 27, 2011Publication date: November 7, 2013Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Chinatsu Furumiya, Takayuki Miyano, Atsuko Nakata, Eri Matsumoto
-
Publication number: 20120269760Abstract: An eye drop composition comprising a carboxyvinyl polymer and a monoterpene, and having a viscosity from 200 to 100,000 mPa·s. The monoterpene may be at least one selected from the group consisting of menthol, camphor and borneol. The carboxyvinyl polymer content may be from 0.001 to 10 w/v % with respect to the total volume of the eye drop composition, and the monoterpene content may be from 0.0001 to 1 w/v % with respect to the total volume of the eye drop composition.Type: ApplicationFiled: September 29, 2010Publication date: October 25, 2012Inventors: Teiko Akagi, Takayuki Miyano, Motoyoshi Inooka
-
Publication number: 20100069323Abstract: Disclosed is a composition for application to skin or mucosa comprising alginic acid and/or salts thereof, which has reduced cytotoxicity against a skin cell or mucosa cell and higher safety, the composition for application to skin or mucosa comprises an alginic acid and/or salts thereof that contains substantially no low-molecular-weight fraction having a molecular weight of 3,500 or less.Type: ApplicationFiled: November 9, 2007Publication date: March 18, 2010Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Tadashi Seto, Takayuki Miyano, Kenichi Haruna, Takahiro Kurose
-
Patent number: 4987522Abstract: The present invention relates to a roof member and illumination device mountable to a ceiling portion of a head guard in a forklift without interfering with each other. The illumination device has a `C` shaped light mounting bracket, and the roof member has an upward facing depression formed in one portion of the peripheral drip edge groove so that the roof member can be inserted in between the upper and lower portion of the light mounting bracket. Also, the roof member has a window portion provided for upper observation, this window portion bulging upwards to improve water drainage.Type: GrantFiled: December 18, 1989Date of Patent: January 22, 1991Assignee: Kabushiki Kaisha Toyoda Jidoshokki SeisakushoInventors: Takayuki Miyano, Shinsuke Nii